Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality
Not yet recruiting
- Conditions
- Hematological Malignancies
- Registration Number
- NCT06258629
- Lead Sponsor
- Sohag University
- Brief Summary
Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Newly diagnosed cases of hematological malignancis.
Exclusion Criteria
- Known cases of hematological malignancies and on treatment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Level of CD200 diagnostic marker assessed by flow cytometry one year Prognostic value of CD200 in hematological malignancies
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the prognostic significance of CD200 expression in hematological malignancies like leukemia and lymphoma?
How does CD200 signaling influence disease progression in multiple myeloma and lymphoma patients?
Are there specific biomarkers that correlate with CD200 levels to predict outcomes in hematological cancers?
What therapeutic strategies target CD200 in hematological malignancies compared to standard-of-care treatments?
What adverse events are associated with CD200-based prognostic assessments in oncology research?